4 results match your criteria: "İzmir Bozyaka Health Practice and Research Center[Affiliation]"
Comparison of safety and efficacy of one shot dilation vs. gradual dilation technique in supine percutaneous nephrolithotomy.
World J Urol
June 2023
Department of Urology, Bezmi Alem Vakıf University, Istanbul, Turkey.
Purpose: To compare the efficacy and safety of gradual dilation (GD) and one-shot dilation (OSD) techniques in patients who underwent supine percutaneous nephrolithotomy (PCNL).
Methods: The data of 176 patients who underwent supine PCNL were reviewed. Eighty-seven patients who underwent OSD were defined as group 1, and 89 patients who underwent GD were defined as group 2.
The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience.
Breast J
January 2023
Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Objective: To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC).
Methods: Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC.
Gastrointestinal Tract Metastases of Invasive Lobular Carcinoma of the Breast: An Immunohistochemical Survey Algorithm.
Eur J Breast Health
October 2022
Department of General Surgery, University of Health Sciences Turkey, İzmir Bozyaka Health Practice and Research Center, İzmir, Turkey.
Invasive lobular carcinoma (ILC) accounts for almost 15% of all breast carcinomas. The potential of ILC to metastasize to the gastointestinal system is significantly greater than that of invasive ductal carcinoma. Gastric metastasis occurred in the ninth year of the follow-up in a patient who was operated on the right breast due to ILC.
View Article and Find Full Text PDFBreast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes.
Sci Rep
October 2021
Department of General Surgery, Izmir Bozyaka Health Practice and Research Center, University of Health Sciences Turkey, Izmir, Turkey.
Article Synopsis
- The study examines the clinical outcomes of breast cancer patients with different metastatic conditions, focusing on those with oligometastatic bone disease (OMBD).
- The findings revealed significant differences in overall survival rates among three groups: no metastasis (16.7 years), OMBD (7.8 years), and widespread metastasis (5.9 years).
- Patients in the OMBD category had varying survival based on the number of bone metastases, indicating that OMBD may require distinct management approaches compared to isolated or widespread bone metastases.